View all newsletters
Receive our newsletter - data, insights and analysis delivered to you

Deals this week: Adlai, Skyhawk, Aerpio Pharmaceuticals

Adlai Nortye Biopharma has raised $50m through a series B financing round from Yuanming Capital.

Adlai Nortye Biopharma has raised $50m through a series B financing round from Yuanming Capital.

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

Matrix Partners China, DT Capital, and Yahui Precision Medicine Fund also participated in the funding round.

Based in China, Adlai Nortye is a biopharmaceutical company engaged in the research and development of cancer immunotherapy drugs.

Skyhawk Therapeutics has raised $40m in equity investment in a seed funding round.

The funding round included the participation of biotech-focused funding companies, technology-focused family investment firms, and other major family investors.

The new investment, along with a recently announced $60m collaboration, brings the total capital raised by the company to $100m.

The company plans to use the funds towards the development of its STAR technology platform, as well as drug candidates in the neurological, oncological and immunological areas.

Based in the US, Skyhawk Therapeutics is a drug discovery and development company.

Aerpio Pharmaceuticals has raised $45m through an underwritten public offering of 11.6 million shares of its common stock priced at $3.85 a share.

The underwriters will receive a 30-day option to buy an additional 1.7 million shares of common stock.

The company plans to use the funds towards working capital and general corporate purposes.

Goodwin Procter is the company’s legal adviser for the offering.

Based in the US, Aerpio Pharmaceuticals is a biopharmaceutical company engaged in the development and commercialisation of treatments for ocular diseases.

“Skyhawk Therapeutics has raised $40m in equity investment in a seed funding round.”

Constellation Pharmaceuticals has filed a registration statement with the US Securities and Exchange Commission (SEC) to raise $86.25m through an initial public offering of shares of its common stock.

J.P. Morgan Securities, Jefferies, BMO Capital Markets, and Oppenheimer & Co were appointed as underwriters to the company for the offering.

Based in the US, Constellation Pharmaceuticals is a biopharmaceutical company that develops therapeutics for the treatment of cancer and inflammatory diseases.

Crinetics Pharmaceuticals has filed a registration statement with the US Securities and Exchange Commission (SEC) to raise $86.25m through an initial public offering of shares.

The funds are intended to be used towards the clinical development of its non-peptide based agonist, CRN00808. The funds will also be used towards other development programmes, working capital and general corporate purposes.

J.P. Morgan Securities, Leerink Partners and Piper Jaffray & Co were appointed as underwriters to the company for the offering.

Based in the US, Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company engaged in the discovery and development of drugs.

CEL-SCI has filed a registration statement with the US Securities and Exchange Commission (SEC) to raise $11m through a private placement of three million shares.

Based in the US, CEL-SCI is a biotechnology company that develops investigational therapies for cancer and other diseases.

Hart & Hart was appointed as the company’s legal adviser for the offering.

Related Companies

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena